A novel drug discovery platform developed by Yale professor Lieping Chen has led to a record $67 million Series A financing—one of the largest Series A financing rounds for a biotech startup and the largest such deal in Yale’s history.

Chen’s technology, which investors hope will lead to new immunotherapy drugs to treat cancer, is being developed by NextCure, Inc., a new biopharmaceutical company.

The deal is unique not only for the size of the investment but for its innovative approach: combining patented technologies with the unique insights of the inventor into tumor microenvironments.